Evotec reaches pre-clinical milestone in Bayer alliance

By Melissa Fassbender

- Last updated on GMT

Evotec and Bayer formed a strategic alliance in October 2012. (Image: iStock/AlexeyVS)
Evotec and Bayer formed a strategic alliance in October 2012. (Image: iStock/AlexeyVS)

Related tags Contract research organization

Evotec AG has received a payment of approximately ‎€5m ($5.62m) as part of its strategic alliance with Bayer – which the company says is “well on track and very successful.”

The Germany-headquartered contract research organization​ (CRO) received the payment for transitioning a program into pre-clinical development for the treatment of endometriosis.

The multi-target endometriosis alliance with Bayer​ was established in October 2012 with the goal of developing three clinical candidates for the treatment of endometriosis.

An Evotec spokesperson told Outsourcing-Pharma.com the five-year alliance “is well on track and very successful​.”

Both companies contribute drug targets and technology infrastructures, sharing responsibility for early research and pre-clinical characterization of potential clinical candidates.

This pre-clinical milestone is again an important step on the way to the achievement of this goal​,” the spokesperson explained.

Related news

Show more

Related products

show more

Related suppliers